BioNTech (BNTX) Stock Forecast & Price Target

$121.72 +2.88 (+2.42%)

(As of 06:03 PM ET)

BioNTech - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
0

Hold
4

Buy
12

Based on 16 Wall Street analysts who have issued ratings for BioNTech in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 4 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for BNTX.

Consensus Price Target

$138.67
13.93% Upside

According to the 16 analysts' twelve-month price targets for BioNTech, the average price target is $138.67. The highest price target for BNTX is $171.44, while the lowest price target for BNTX is $122.00. The average price target represents a forecasted upside of 13.93% from the current price of $121.72.

Get the Latest News and Ratings for BNTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BioNTech and its competitors.

BNTX Analyst Ratings Over Time

Type	Current Forecast 12/7/23 to 12/6/24	1 Month Ago 11/7/23 to 11/6/24	3 Months Ago 9/8/23 to 9/7/24	1 Year Ago 12/7/22 to 12/7/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	8 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)
Hold	4 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$138.67	$134.69	$109.09	$151.46
Forecasted Upside	13.93% Upside	26.31% Upside	21.29% Upside	48.60% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

Elon’s 56-character tweet puts him in firing line (Ad)

In my new documentary, you’ll discover that the government had the opportunity to make America 100% energy independent 50 years ago. But instead, they chose not to, making us dependent on oil, gas, coal, solar panels and wind turbines. In reality, we could have avoided all of it by expanding an energy grid that we already built, commissioned by Ronald Reagan.

Click here now to watch my new exposé.

BNTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BNTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BioNTech Stock vs. The Competition

Type	BioNTech	Medical Companies	S&P 500
Consensus Rating Score	2.81	2.81	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	14.44% Upside	26,645.78% Upside	8.37% Upside
News Sentiment Rating	Positive News See Recent BNTX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/2/2024	BMO Capital Markets 4 of 5 stars		Reiterated Rating	Outperform
11/27/2024	Canaccord Genuity Group 1 of 5 stars		Boost Target	Buy ➝ Buy	$171.00 ➝ $171.44	+44.63%
11/26/2024	JPMorgan Chase & Co. 3 of 5 stars		Lower Target	Neutral ➝ Neutral	$124.00 ➝ $122.00	+1.03%
11/19/2024	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	H. Gillis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$130.00	+27.61%
11/19/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Kasimov Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	In-Line ➝ Outperform	$110.00 ➝ $125.00	+22.71%
11/18/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$150.00 ➝ $150.00	+50.42%
Get the Latest News and Ratings for BNTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.
11/8/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Shibutani Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$90.00 ➝ $137.00	+26.99%
11/5/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$132.00 ➝ $122.00	+10.28%
10/7/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$97.00 ➝ $136.00	+10.88%
9/24/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$93.00 ➝ $145.00	+28.26%
9/19/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$95.00 ➝ $150.00	+33.87%
9/18/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$97.00 ➝ $131.00	+5.04%
9/17/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$96.00 ➝ $150.00	+21.49%
9/16/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$125.00 ➝ $150.00	+23.75%
8/2/2024	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
1/5/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform
5/17/2023	Redburn Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$165.00 ➝ $170.00	+60.98%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:21 AM ET.

Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, December 4, 2024. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com.

BioNTech
Bull Case

Here are some ways that investors could benefit from investing in BioNTech SE:

BioNTech SE reported a significant earnings per share (EPS) of $0.81 for the latest quarter, exceeding the consensus estimate of ($1.26) by $2.07, indicating strong financial performance.
The company achieved a remarkable revenue of $1.24 billion for the quarter, far surpassing analysts' expectations of $514.08 million, showcasing robust demand for its products.
Year-over-year revenue growth of 38.9% highlights BioNTech SE's ability to expand its market presence and increase sales effectively.
Recent institutional investments, including a 261.2% increase in shares by Candriam S.C.A., suggest growing confidence among large investors in BioNTech SE's future prospects.
The current stock price reflects a positive market sentiment, making it an attractive option for investors looking for growth opportunities in the biotechnology sector.

BioNTech
Bear Case

Investors should be bearish about investing in BioNTech SE for these reasons:

BioNTech SE has a negative net margin of 15.16%, indicating that the company is currently spending more than it earns, which could raise concerns about long-term profitability.
The company is projected to post an EPS of -3.68 for the current fiscal year, suggesting potential challenges in maintaining profitability moving forward.
Despite recent revenue growth, the negative return on equity of 2.35% indicates that the company is not generating sufficient returns on shareholders' equity, which may deter some investors.
Recent fluctuations in institutional holdings, with some hedge funds reducing their stakes, could signal uncertainty about the company's future performance.
The biotechnology sector can be highly volatile, and any setbacks in product development or regulatory approvals could adversely affect BioNTech SE's stock performance.

BNTX Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for BioNTech is $138.67, with a high forecast of $171.44 and a low forecast of $122.00.
: 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 4 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BNTX shares.
: According to analysts, BioNTech's stock has a predicted upside of 13.93% based on their 12-month stock forecasts.
: Over the previous 90 days, BioNTech's stock had 5 upgrades by analysts.
: BioNTech has been rated by research analysts at Bank of America, Berenberg Bank, BMO Capital Markets, Canaccord Genuity Group, Deutsche Bank Aktiengesellschaft, Evercore ISI, HC Wainwright, HSBC, Jefferies Financial Group, JPMorgan Chase & Co., Morgan Stanley, TD Cowen, The Goldman Sachs Group, and UBS Group in the past 90 days.
: Analysts like BioNTech more than other "medical" companies. The consensus rating score for BioNTech is 2.81 while the average consensus rating score for "medical" companies is 2.81. Learn more on how BNTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Elon’s 56-character tweet puts him in firing line (Ad)

Click here now to watch my new exposé.

This page (NASDAQ:BNTX) was last updated on 12/6/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNTech (BNTX) Stock Forecast & Price Target